Downloaded from http://bjo.bmj.com/ on March 19, 2015 - Published by group.bmj.com
Clinical science
Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data Daniel Barthelmes,1,2 Richard Walton,1 Anna E Campain,1 Judy M Simpson,3 Jennifer J Arnold,4 Ian L McAllister,5 Robyn H Guymer,6 Alex P Hunyor,1,7 Rohan W Essex,8 Nigel Morlet,9 Mark C Gillies,1 for the Fight Retinal Blindness! Project Investigators 1
The Save Sight Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia 2 Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland 3 Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia 4 Marsden Eye Specialists, Parramatta, New South Wales, Australia 5 The Lions Eye Institute, Perth, Western Australia, Australia 6 Center for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia 7 Retina Associates, Chatswood, New South Wales, Australia 8 Department of Ophthalmology, Canberra Hospital, Garran, Australian Capital Territory, Australia 9 Department of Population Health, University of Western Australia, Perth, Western Australia, Australia Correspondence to Professor Mark Gillies, Save Sight Institute, South Block, 8 Macquarie St., Sydney, NSW 2001, Australia; [email protected] Received 9 May 2014 Accepted 16 August 2014 Published Online First 23 September 2014
To cite: Barthelmes D, Walton R, Campain AE, et al. Br J Ophthalmol 2015;99:359–364.
ABSTRACT Aim To describe outcomes of eyes with wet age-related macular degeneration (AMD) subdivided by lesion activity in a large multicentre cohort study. Methods Treatment-naive eyes with subfoveal choroidal neovascularisation receiving antivascular endothelial growth factor therapy enrolled in the Fight Retinal Blindness observational study were included. Lesions were graded at each visit as active if there was intraretinal or subretinal fluid attributable to leak from choroidal neovascularisation lesion or fresh haemorrhage. Eyes were divided into four groups; based on the proportion of visits, each eye was graded as active during the first 12 months of treatment ( persistent, high, moderate and low activity). Results 655 eyes were included. Similar mean visual acuity changes compared with baseline were observed in all four groups at 12 months (+6.8, +8.3, +6.2 and +5.5 letters for the low, moderate, high and persistent groups, respectively; p5 logMAR letters) improvements observed at 12 months of 6.8, 8.3, 6.2 and 5.5 letters for the low, moderate, high and persistent groups, respectively (table 2). Each group had statistically significantly improved VA at 12 months compared with the index visit (p
Clinical science
Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data Daniel Barthelmes,1,2 Richard Walton,1 Anna E Campain,1 Judy M Simpson,3 Jennifer J Arnold,4 Ian L McAllister,5 Robyn H Guymer,6 Alex P Hunyor,1,7 Rohan W Essex,8 Nigel Morlet,9 Mark C Gillies,1 for the Fight Retinal Blindness! Project Investigators 1
The Save Sight Institute, Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia 2 Department of Ophthalmology, University Hospital Zurich, University of Zurich, Zurich, Switzerland 3 Sydney School of Public Health, University of Sydney, Sydney, New South Wales, Australia 4 Marsden Eye Specialists, Parramatta, New South Wales, Australia 5 The Lions Eye Institute, Perth, Western Australia, Australia 6 Center for Eye Research Australia, University of Melbourne, Royal Victorian Eye and Ear Hospital, Melbourne, Victoria, Australia 7 Retina Associates, Chatswood, New South Wales, Australia 8 Department of Ophthalmology, Canberra Hospital, Garran, Australian Capital Territory, Australia 9 Department of Population Health, University of Western Australia, Perth, Western Australia, Australia Correspondence to Professor Mark Gillies, Save Sight Institute, South Block, 8 Macquarie St., Sydney, NSW 2001, Australia; [email protected] Received 9 May 2014 Accepted 16 August 2014 Published Online First 23 September 2014
To cite: Barthelmes D, Walton R, Campain AE, et al. Br J Ophthalmol 2015;99:359–364.
ABSTRACT Aim To describe outcomes of eyes with wet age-related macular degeneration (AMD) subdivided by lesion activity in a large multicentre cohort study. Methods Treatment-naive eyes with subfoveal choroidal neovascularisation receiving antivascular endothelial growth factor therapy enrolled in the Fight Retinal Blindness observational study were included. Lesions were graded at each visit as active if there was intraretinal or subretinal fluid attributable to leak from choroidal neovascularisation lesion or fresh haemorrhage. Eyes were divided into four groups; based on the proportion of visits, each eye was graded as active during the first 12 months of treatment ( persistent, high, moderate and low activity). Results 655 eyes were included. Similar mean visual acuity changes compared with baseline were observed in all four groups at 12 months (+6.8, +8.3, +6.2 and +5.5 letters for the low, moderate, high and persistent groups, respectively; p5 logMAR letters) improvements observed at 12 months of 6.8, 8.3, 6.2 and 5.5 letters for the low, moderate, high and persistent groups, respectively (table 2). Each group had statistically significantly improved VA at 12 months compared with the index visit (p
